The new board of directors at Aeolus (formerly Incara) Pharmaceuticals has given its approval for the firm to seek a clinical trial for a compound to be used in cancer radiation therapy.

Aeolus said it hoped to launch the trial in the first quarter of 2005.

The company is also pursuing a drug to treat Lou Gehrig’s disease. That trial could begin in September.

Aeolus wants to pursue development of a compound that helps protect healthy cells during radiation therapy. The compound has also inhibited tumor growth in animal models through the inhibition of blood vessel formation for tumors.